asteatosis in hemodialyzed patient
Conditions
Interventions
Base treatment + heparinoid(Initial to week2)
Base treatment + heparinoid(Initial to week8)
Sponsors
Nippon medical school hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Chronic renal failure patients who regularly receive hemodialysis two or three times a week and are not likely to have a serious treatment change or acute symptoms during the study period. (2) Patients with asteatosis at hypochondriac region at time of initial of treatment (3) Patients with pruritus at time of initial of treatment (4) Patients who signed informed consent. (5) Patients aged 20 to 80 years at time of signing the consent form (6) Patients of either sex
Exclusion criteria
Exclusion criteria: (1) Patients who received heparinoid- or urea -containing drugs, or petrolatum within three weeks before signing the consent form. (2) Patients with/ with the past of extensive complications of the skin (burn, psoriasis etc.) (3) Patients with allergy to heparinoid (4) Patients with hemorrhagic blood disease (hemophilia, thrombocytopenia, purpura etc.) (5) Patients who are expected a few bleeding causes a serious result. (6) Patients who are pregnant, or possibly pregnant women. (7)Patients who participated in other clinical study within 4 months before starting study. (8) Patients who are unsuitable to the study at the investigator's discretion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The water content of the stratum corneum at week4 | — |
Secondary
| Measure | Time frame |
|---|---|
| Efficacy (The water content of the stratum corneum, pruritus, DLQI), Safety | — |
Countries
Japan
Contacts
Public ContactShuichi tsuruoka
Nippon medical school hospital Nephrology
Outcome results
None listed